跳至主要内容
临床试验/CTRI/2012/01/002348
CTRI/2012/01/002348招募中2 期

Clinical Evaluation of Bilvadi Leha in the Management of Irritable Bowel Syndrome (IBS) - ACT- IBS-2010

Department of AYUSH Ministry of Health Family Welfare Government of India0 个研究点目标入组 150 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patients of either sex with age between 18 and 65 years
  • 2. Known case of IBS as per Rome III criteria :
  • (Symptoms of recurrent abdominal pain or discomfort and a marked change in
  • bowel habit for atleast six months, with symptoms experienced on atleast 3
  • days/month in the last 3 months associated with two or more of the following:
  • · Pain is relieved by defecation
  • · Onset associated with change of frequencey of stools
  • · Onset assoicated with a change in form (appearance) of stools.
  • (Diagnosis to be confirmed by using the IBS module questionnaire)
  • 3. Willing and able to participate in the study

排除标准

  • 1. Patients with bleeding per rectum.
  • 2. Mixed infection with parasites like round worms, hook worms etc.
  • 3. Patients with evidence of malignancy
  • 4. Patients with Diabetes Mellitus {B.S. (F) > 126 mg% and / or B.S. (2 hr. PP)
  • >200 mg% OR HbA1c > 6.5%}.
  • 5. Patient with poorly controlled Hypertension ( > 160 / 100 mm Hg)
  • 6. Patients on prolonged ( > 6 weeks) medication with corticosteoids, antidepressants,
  • anticholinergics, etc. or any other drugs that may have an influence on the
  • outcome of the study.
  • 7. Patients suffering from major systemic illness necessitating long term drug
  • treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal
  • disorders, etc.)
  • 8. Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome,
  • Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
  • 9. Symptomatic patient with clinical evidence of Heart failure.
  • 10. Patients with concurrent serious hepatic disorder (defined as Aspartate Amino
  • Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin,
  • Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders
  • (defined as S. Creatinine >1.2mg/dL), Severe Pulmonary Dysfunction
  • (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease
  • [COPD]), or any other condition that may jeopardize the study.
  • 11. Alcoholics and/or drug abusers.
  • 12. H/o hypersensitivity to the trial drug or any of its ingredients.
  • 13. Pregnant / lactating woman.
  • 14. Patients who have completed participation in any other clinical trial during the
  • past six (06) months.
  • 15. Any other condition which the Principal Investigator thinks may jeopardize the

研究者

发起方
Department of AYUSH Ministry of Health Family Welfare Government of India

相似试验